Target intelligence / Profile preview

Helicobacter pylori 23S ribosomal RNA domain V (23S rRNA domain V) (23S rRNA domain V)

Target
23S rRNA domain V
Molecular classification
Ribosomal RNA, Nucleic acid
01

Overview

The 23S ribosomal RNA (rRNA) domain V in Helicobacter pylori is a critical structural and functional component of the bacterial 50S ribosomal subunit. It forms the core of the peptidyl transferase center (PTC), which is responsible for catalyzing peptide bond formation during protein synthesis (Taylor et al., 1997, Antimicrob. Agents Chemother.). This domain is the primary therapeutic target for macrolide antibiotics, such as clarithromycin, which is a cornerstone of H. pylori eradication therapy (Megraud, 2004, Gut). Macrolides bind to specific nucleotides within domain V, effectively blocking the nascent peptide exit tunnel and halting translation (Vester & Douthwaite, 2001, Antimicrob. Agents Chemother.). Mutations within this domain, particularly at positions A2142 and A2143, are the leading cause of clinical resistance to clarithromycin (Versalovic et al., 1996, Antimicrob. Agents Chemother.). These mutations significantly impact the efficacy of treatment regimens for H. pylori-associated conditions like peptic ulcers and gastric cancer (Mégraud & Lehours, 2007, Clin. Microbiol. Rev.). Understanding the structural integrity of domain V is essential for monitoring antibiotic susceptibility and developing next-generation antimicrobial agents.

Other names
Peptidyl transferase center23S rRNALarge ribosomal subunit RNADomain V of 23S rRNA
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the 23S rRNA and blocking the nascent peptide exit tunnel.

03

Biological functions

Protein synthesisPeptidyl transferase activityTranslation
04

Disease associations

Helicobacter pylori infectionGastritisPeptic ulcer diseaseGastric cancer
05

Safety considerations

Development of antimicrobial resistanceCross-resistance among macrolidesGastrointestinal distressDrug-drug interactions via CYP3A4 inhibition
06

Interacting drugs

Clarithromycin

4 more in the full profile.

07

Biomarkers

A2142G mutationA2143G mutationA2142C mutation

Beyond the preview

Go deeper on Helicobacter pylori 23S ribosomal RNA domain V (23S rRNA domain V) (23S rRNA domain V).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Helicobacter pylori 23S ribosomal RNA domain V (23S rRNA domain V) (23S rRNA domain V).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call